Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 670 matching drugs for CDK2 — including drugs targeting any of its 134 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
alvocidib, paclitaxel CDK2 Direct 2
alvocidib, docetaxel CDK2 Direct 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK2 Direct 1
trilaciclib CDK2 Direct 1
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib KDR SSL via KDR yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK6 SSL via CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDR SSL via KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK14 SSL via MAPK14 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CA SSL via PIK3CA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib WEE1 SSL via WEE1 3
afatinib ERBB4 SSL via ERBB4 yes 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
gemcitabine RRM1 SSL via RRM1 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
pembrolizumab, belzutifan, lenvatinib KDR SSL via KDR 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab RRM1 SSL via RRM1 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin RRM1 SSL via RRM1 2
abemaciclib CDK4 SSL via CDK4 yes 2
abemaciclib CDK6 SSL via CDK6 yes 2
adavosertib, radiation therapy WEE1 SSL via WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
alvocidib, paclitaxel CDK1 SSL via CDK1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK5 SSL via CDK5 2
alvocidib, paclitaxel CDK6 SSL via CDK6 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan KDR SSL via KDR 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine RRM1 SSL via RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 KDR SSL via KDR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment MAPK14 SSL via MAPK14 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK6 SSL via CDK6 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
cabozantinib KDR SSL via KDR yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDR SSL via KDR 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab RRM1 SSL via RRM1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK6 SSL via CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KDR SSL via KDR 2
everolimus MTOR SSL via MTOR yes 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KDR SSL via KDR 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine RRM1 SSL via RRM1 2
lenvatinib, pembrolizumab KDR SSL via KDR 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KDR SSL via KDR 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab RRM1 SSL via RRM1 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed RRM1 SSL via RRM1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KDR SSL via KDR 2
nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 2
nintedanib KDR SSL via KDR yes 2
nintedanib, pembrolizumab KDR SSL via KDR 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu RRM1 SSL via RRM1 2
palbociclib CDK4 SSL via CDK4 yes 2
palbociclib CDK6 SSL via CDK6 yes 2
pazopanib KDR SSL via KDR yes 2
pembrolizumab, lenvatinib KDR SSL via KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KDR SSL via KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KDR SSL via KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin RRM1 SSL via RRM1 2
ramucirumab KDR SSL via KDR yes 2
ramucirumab, paclitaxel KDR SSL via KDR 2
regorafenib KDR SSL via KDR yes 2
regorafenib, laboratory biomarker analysis KDR SSL via KDR 2
selumetinib, medi4736, tremelimumab MAP2K1 SSL via MAP2K1 2
sorafenib, administered orally, ct/mri KDR SSL via KDR 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel RRM1 SSL via RRM1 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KDR SSL via KDR 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) KDR SSL via KDR 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) MAP2K1 SSL via MAP2K1 1
9-ing-41, retifanlimab, gemcitabine, abraxane RRM1 SSL via RRM1 1
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, abemaciclib CDK6 SSL via CDK6 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK6 SSL via CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK4 SSL via CDK4 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.